| Pei et al., 2016 (28) |
MMP-2 and MMP-9 |
Bisdemethoxycurcumin inhibits ovarian cancer cells via reducing oxidative stress-mediated expression of MMP-2 and -9. |
| Wang et al., 2016 (27) |
MMP-2 and MMP-9 |
Fe-MIL-101 suppresses the proliferation of human SKOV3 ovarian cancer cells via downregulation the expression of MMP-2 and -9. |
| Vos et al., 2016 (37) |
MMP-14 |
Patients with double expression of MMP-14 and CD44 have a poor prognosis. |
| Fu et al., 2015 (11) |
MMP-2 |
Tumor-derived MMP-2 expression predicts a lower overall survival rate and could be an independent prognostic factor in patients with ovarian cancer. |
| Gonzalez-Villasana et al., 2015 (15) |
MMP-2 |
Zoledronic acid exerts robust inhibitory activity on cell invasion of HeyA8-MDR and OVCAR-5 ovarian cancer cells through decreasing the intracellular level of MMP-2. |
| Liu etal., 2015 (33) |
MMP-12 |
MMP-12 82 A/G polymorphism increases the susceptibility to ovarian cancer despite not being significantly associated with overall cancer risk. |
| Chen et al., 2015 (32) |
MMP-12 |
MMP-12 82 A/G polymorphism is a genetic risk factor for epithelial ovarian carcinoma. |
| Gao et al., 2014 (14) |
MMP-2 |
Catalpol suppresses proliferation and accelerated apoptosis of OVCAR-3 ovarian cancer cells via promoting microRNA-200 expression and reducing MMP-2 signaling. |
| Bandaru et al., 2014 (26) |
MMP-9 |
Filamin B (FLNB) suppresses the growth and metastasis of human ovarian cancer by down-regulating the activity of MMP-9 and secretion of vascular endothelial growth factor-A (VEGF-A). |
| Trudel et al., 2014 (36) |
MMP-14 |
Higher expression of MMP-14 is associated with lower progression and better prognosis of ovarian carcinoma. |
| Wang et al., 2013 (10) |
MMP-2 |
MMP-2 plays a positive role in the invasion and metastasis of ovarian cancer. |
| Al-Alem et al., 2013 (30) |
MMP-7 and MMP-10 |
Targeted inhibition of MMP-7 and MMP-10 may provide potential ovarian cancer therapeutic strategy. |
| Li et al., 2013 (25) |
MMP-9 |
Increased expression of MMP-9 is associated with poor prognosis in ovarian cancer. |
| Kaimal et al., 2013 (38) |
MMP-14 |
MMP-14-dependent invasion and metastasis is effectively inhibited by intraperitoneal administration of monoclonal MMP-14 antibody. |
| Zhao et al., 2012 (21) |
MMP-7 |
Triptolide inhibits the migration and invasion of ovarian cancer cells by suppression of MMP-7. |
| Chang et al., 2012 (19) |
MMP-7 |
Mesothelin enhances ovarian cancer invasion by MMP-7 expression through the MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) and JNK (c-Jun N-terminal kinase) signal transduction pathways. |
| Ghosh et al., 2012 (34) |
MMP-9 and MMP-13 |
Activation of PI3K/AKT (phosphatidylinositol-3-kinase) and p38 MAPK by VEGF activates MMP-9 and MMP-13, leading to the invasion of SKOV-3 cells. |
| Agarwal et al., 2010 (4) |
MMP-1 |
MMP-1-PAR1 (protease-activated receptor-1) activation induces secretion of several angiogenic factors in ovarian carcinoma cells, leading to cell proliferation, tube formation and migration. |
